Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OptimizeRx Corporation - Common Stock (NQ:OPRX)

5.080 +5.080 (+1015900.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about OptimizeRx Corporation - Common Stock

< Previous 1 2 3 Next >
MissionIRNewsBreaks – OptimizeRx Corp. (NASDAQ: OPRX) Secures $35 Million Senior Credit Facility
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
OptimizeRx to Participate in Upcoming Investor Conferences
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx’s Authenticated EHR Network
Powered by OptimizeRx’s new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers 
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Launches Programmatic Access to Authenticated EHR Advertising at Scale
Expands life sciences marketers’ reach at the validated point of care, enabling DSPs to directly integrate with OptimizeRx’s trusted EHR network for the first time 
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Releases 2026 Environmental, Social, and Governance (ESG) Report
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Sets Fourth Quarter and Full Year 2025 Financial Results Conference Call for March 5, 2026, at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx and Experian Collaborate to Improve Privacy-Safe Identity Resolution in Healthcare Marketing
Life science marketers will be able to better measure the exposed audiences for a more complete, accurate, and transparent view of campaign engagement and effectiveness 
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network
Strategic Partnerships Add Exclusivity in Leading EHR, e-Prescription, and Technology Companies, Increasing NPI Reach by 37% 
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Reports Third Quarter 2025 Financial Results and Increases Fiscal Year 2025 Guidance
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Sets Third Quarter 2025 Conference Call for November 6, 2025, at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx to Participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevant Audiences Through Out-of-Home Healthcare Advertising
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Corporation Appoints CEO Steve Silvestro to Board of Directors
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
Simulmedia and OptimizeRx Announce Partnership from the Cannes Lions
From Simulmedia
Via Business Wire
News headline image
OptimizeRx to Participate in Upcoming Investor Conferences
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) Report
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations
No Stockholder Action Required at this Time 
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer
Silvestro has a demonstrated record of accelerating revenue growth, expanding brand relevance, and building a market-leading team 
From OptimizeRx Corporation
Via GlobeNewswire
News headline image
OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET
From OptimizeRx Corporation
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.